HomeCompareROE vs MRK

ROE vs MRK: Dividend Comparison 2026

ROE yields 1.13% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $36.4K in total portfolio value
10 years
ROE
ROE
● Live price
1.13%
Share price
$35.26
Annual div
$0.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.3K
Annual income
$121.80
Full ROE calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — ROE vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodROEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ROE + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ROE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ROE
Annual income on $10K today (after 15% tax)
$96.20/yr
After 10yr DRIP, annual income (after tax)
$103.53/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,493.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ROE + MRK for your $10,000?

ROE: 50%MRK: 50%
100% MRK50/50100% ROE
Portfolio after 10yr
$39.5K
Annual income
$5,117.79/yr
Blended yield
12.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ROE
Analyst Ratings
3
Buy
1
Hold
1
Sell
Consensus: Buy
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ROE buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricROEMRK
Forward yield1.13%2.81%
Annual dividend / share$0.40$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$21.3K$57.7K
Annual income after 10y$121.80$10,113.78
Total dividends collected$1.2K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ROE vs MRK ($10,000, DRIP)

YearROE PortfolioROE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,813$113.17$11,213$373.04$400.00MRK
2$11,684$114.37$12,667$512.06$983.00MRK
3$12,618$115.50$14,439$708.14$1.8KMRK
4$13,618$116.57$16,640$988.16$3.0KMRK
5$14,689$117.57$19,432$1,394.07$4.7KMRK
6$15,835$118.52$23,057$1,992.90$7.2KMRK
7$17,063$119.42$27,889$2,894.79$10.8KMRK
8$18,378$120.26$34,518$4,286.29$16.1KMRK
9$19,785$121.05$43,912$6,494.35$24.1KMRK
10$21,292$121.80$57,714$10,113.78$36.4KMRK

ROE vs MRK: Complete Analysis 2026

ROEStock

ROE holds a portfolio of US, large- and mid-cap stocks believed to have the highest quality, valuation, dividend potential, and growth metrics across sectors. The fund aims for an equally weighted and sector-optimized portfolio. The sub-adviser's proprietary quantitative screen evaluates securities while attempting a sector-optimized selection by using metrics that vary in quality and robustness. Factors such as ROE, ROI, P/E ratio, dividend yield, projected growth estimates, and earnings momentum are considered but only metrics that best define a sector are utilized. The top 50-100 stocks based on their weighted average rank on each factor are selected. The sub-adviser monitors investments through its quantitative and systematic approach to best position the fund for changing economic trends valuations or earnings. As an actively managed fund, positions may change depending on the sub-adviser's assessment and discretion. On Apr. 22, 2024, the fund appended Equal Weight to its name.

Full ROE Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ROE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ROE vs SCHDROE vs JEPIROE vs OROE vs KOROE vs MAINROE vs JNJROE vs ABBVROE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.